Cited by

• Pharmacodynamic Studies to Demonstrate Bioequivalence of Oral Inhalation Products.

  Hendeles L, Daley-Yates PT, Hermann R, De Backer J, Dissanayake S, Horhota ST. Hendeles L, et al. AAPS J. 2015 May;17(3):758-68. doi: 10.1208/s12248-015-9735-7. Epub 2015 Feb 26. AAPS J. 2015. PMID: 25716149 Free PMC article.
• In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory Approaches.

  Forbes B, Bäckman P, Christopher D, Dolovich M, Li BV, Morgan B. Forbes B, et al. AAPS J. 2015 Jul;17(4):837-52. doi: 10.1208/s12248-015-9763-3. Epub 2015 May 5. AAPS J. 2015. PMID: 25940082 Free PMC article. Review.
• Innovating on Inhaled Bioequivalence: A Critical Analysis of the Current Limitations, Potential Solutions and Stakeholders of the Process.

  Gallegos-Catalán J, Warnken Z, Bahamondez-Canas TF, Moraga-Espinoza D. Gallegos-Catalán J, et al. Pharmaceutics. 2021 Jul 9;13(7):1051. doi: 10.3390/pharmaceutics13071051. Pharmaceutics. 2021. PMID: 34371741 Free PMC article. Review.
• Pulmonary vascular effects of pulsed inhaled nitric oxide in COPD patients with pulmonary hypertension.

  Hajian B, De Backer J, Vos W, Van Holsbeke C, Ferreira F, Quinn DA, Hufkens A, Claes R, De Backer W. Hajian B, et al. Int J Chron Obstruct Pulmon Dis. 2016 Jul 5;11:1533-41. doi: 10.2147/COPD.S106480. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27462149 Free PMC article. Clinical Trial.
• Changes in ventilation-perfusion during and after an COPD exacerbation: an assessment using fluid dynamic modeling.

  Hajian B, De Backer J, Vos W, van Geffen WH, De Winter P, Usmani O, Cahn T, Kerstjens HA, Pistolesi M, De Backer W. Hajian B, et al. Int J Chron Obstruct Pulmon Dis. 2018 Mar 6;13:833-842. doi: 10.2147/COPD.S153295. eCollection 2018. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 29563783 Free PMC article. Clinical Trial.